Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)

NCT01271712 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

199

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastrointestinal Stromal Tumors

Interventions

DRUG: Regorafenib (Stivarga, BAY73-4506)
DRUG: Placebo
DRUG: Best supportive care

Sponsor

Bayer